For the second time in a row, the ILIAD project has been awarded the SIRIC label for 5 years!
Led by the CHU de Nantes, the CHU d'Angers and the Institut de Cancérologie de l'Ouest, the renewal of the SIRIC ILIAD by the Institut National du Cancer is proof of the excellence of cancer research in the Nantes-Angers research site.
Supported by the Pays de la Loire Region, SIRIC ILIAD's mission is to conduct high-level multidisciplinary research, thanks to the expertise of the project's partners: INSERM, CNRS, GIP Arronax, the Universities of Nantes and Angers, Ecole Centrale de Nantes, the Registre des cancers Loire-Atlantique Vendée and Atlanpole.
The project presented on this website is about the first labelling. Follow us on the social networks (at the bottom of the page) to find out when you can discover the new project!
SIRIC ILIAD 2018-2022
During four days, 20 participants will deepen their knowledge in some of the main research areas in nuclear medicine, with a focus on alpha emitting radionuclides (astatine-211 in particular). [...]
The conference “Living and working with cancer” was held on Wednesday 23 November at the Cité des sciences et de l’industrie in Paris. This conference brought together more than [...]
After 5 years of research, the REWORK programme of SIRIC ILIAD is about to release a toolbox for patients with breast cancer, which includes materials to help them return to work. An achievement [...]
The annual Clarivate – Highly Cited Researchers ranking has, for the seventh consecutive year, recognised Professor Philippe Moreau, Director of SIRIC ILIAD, as a Highly Cited Researcher in [...]
On October 18th, the French PDX network and the Organoids research group organised, with the support of the SIRIC ILIAD and the CRCI²NA, a hybrid colloquium : Modeling tumor development and [...]
As part of the National Multiple Myeloma Information Day (JNM 2022) of the AF3M (Association Française des Malades du Myélome Multiple), the association has released a new information bulletin [...]
On Saturday 15 October, SIRIC ILIAD was present at the National Information Day on Multiple Myeloma (JNM 2022) of the AF3M (French Association of Multiple Myeloma Patients) in Nantes. For the [...]
What if acting on the cells surrounding the tumour could improve the effectiveness of treatments? On 14 September 2022, a team from the SIRIC ILIAD specialising in breast cancer published a [...]